Aktienanalyse zu Bone Biologics Corp (BBLG)BBLGBone Biologics Corp

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

BBLG is not a good buy right now due to its current price of $0.32, which is significantly down 79.29% year-to-date, and an RSI of 26.029 indicating it is oversold. The company has consistently reported negative net income, with the latest quarter showing a loss of $617,651. The main risk is its declining financial performance, as evidenced by a forward P/E ratio of 0, indicating no expected earnings growth in the near term.